Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...
The day your car won’t start isn’t the best time to shop for a new car battery. But according to our research, that’s exactly what most people do. You’ll probably have to replace the car battery once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback